multibagg.ai

US and Israel started their war on Iran on 28th February 2026. 6 weeks down the road, Q4 results season is in full swing. Every analyst, every fund manager, every retail investor has one question in their mind: which companies got hit, and which ones managed the crisis well? But the problem is that there are 1000+ companies reporting in the next few weeks. Going through each one manually is a full-time job. Almost impossible. So we built a live q4 earnings tracker. Open it, pick a sector. Say Pharma. You instantly see how many companies beat estimates, how many missed, average sales growth, average profit growth. If you want to go deeper on a specific company? The full report is right there. If you want to see who is posting the highest revenue growth this quarter? There is a leaderboard. If you want to compare this quarter with COVID quarter 6 years back? You can go back up to 10 years. Live earnings tracker is a complete picture of how Indian companies are performing, built for people who do not have 8 hours a day to read balance sheets.

DELHIVERY: DELHIVERY FY26 AUDITED REVENUE AT ₹10,486 CR, UP 17% YOY; EBITDA ₹764 CR (7.3%), PAT ₹347 CR PRE-INTEGRATION. FREE CASH FLOW STOOD AT ₹89 CR, CASH BALANCE AT ₹4,555 CR.

FTAS AND LOWER IMPORT DUTIES COULD SUPPORT INDIA'S FDI INFLOWS, ADB CHIEF ECONOMIST SAYS, AS NET FDI FELL FROM $38.6B TO $28B IN FY23.

IRFC LOAN BOOK SEEN CROSSING ₹1 LAKH CRORE IN FY27, BOOSTING FUNDING FOR INDIAN RAILWAYS AND EXPANDING ITS ASSET BASE OVER THE NEXT 2 YEARS.

INDIA FACES A DOUBLE SHOCK AS HIGHER GOLD DUTY AND A FUEL-PRICE SPIKE PRESSURE FX RESERVES, INFLATION AND ENERGY SECURITY, ADDING HEADWINDS FOR GROWTH AND THE BROADER ECONOMY.

STYLAMIND: STYLAM INDUSTRIES FILED ITS Q4 FY26 CALL TRANSCRIPT; NEW MANAK TABRA LAMINATE PLANT EXPECTED TO START COMMERCIAL PRODUCTION BY JUN–MID-JUL, WITH ₹300–400 CR REVENUE TARGET IN THE NEXT 3 QUARTERS.

NCC: NCC LTD RELEASED THE AUDIO RECORDING OF ITS POST-RESULTS ANALYST CALL FOR Q4 AND FY ENDED 31 MAR 2026, NOW AVAILABLE ON THE COMPANY WEBSITE.

NCC: NCC SUBMITTED AUDITED STANDALONE & CONSOLIDATED RESULTS FOR Q4 AND FY26 TO NSE & BSE, HIGHLIGHTING YEAR-END FINANCIALS FOR THE MAR 2026 PERIOD.

LATENTVIEW: LATENTVIEW POSTED Q4FY26 REVENUE OF ₹2,886M, FY26 REVENUE AT ₹10,602M UP 24.3% YOY, WITH Q4 ADJUSTED EBITDA MARGIN AT 24.1% AND FY26 PAT OF ₹2,021M. CROSSED ₹1,000 CRORE REVENUE MARK IN FY26.

NEULANDLAB: NEULAND LABS Q4FY26 REVENUE JUMPS 135% YOY TO ₹788.7CR, EBITDA AT ₹319.4CR (40.5%), PAT ₹212.5CR. FY26 REVENUE ROSE 37% TO ₹2,053.1CR; NET DEBT STAYS NEGATIVE AT -₹157CR.

LATENTVIEW: LATENT VIEW ANALYTICS CIRCULATES INVESTOR PRESENTATION AHEAD OF 18 MAY 2026 EARNINGS CALL; FY26 OPERATING REVENUE ₹10,602M, ADJUSTED EBITDA ₹2,438M, PAT ₹2,021M, EPS ₹9.59.

TATVA: TATVA CHINTAN FILES Q4FY26/FY26 INVESTOR PRESENTATION: REVENUE ₹1,341MN IN Q4, FY26 REVENUE ₹5,059MN (+32% YOY), PAT ₹421MN VS ₹57MN IN FY25, EBITDA MARGIN IMPROVES TO 18%.

HIRECT: BOARD APPROVED AUDITED STANDALONE AND CONSOLIDATED RESULTS FOR FY26, AUDIT REPORT CARRIES UNMODIFIED OPINION, AND RECOMMENDED A ₹1.40/SH DIVIDEND (70% OF ₹2) FOR AGM APPROVAL.

BORORENEW: BOROSIL RENEWABLES FY26 STANDALONE SALES JUMPED 38% YOY TO ₹1,534.8CR, EBITDA SURGED 172% TO ₹491.7CR; Q4 SALES WERE ₹437.6CR AND EBITDA ₹144.6CR, HELPED BY HIGHER REALISATIONS, ANTIDUMPING SUPPORT AND CAPACITY EXPANSION

AMBUJA CEMENT TO PRIORITISE PROJECT COMPLETION EVEN AS CAPEX SLOWS, AS EXECUTION LAGGED DUE TO CONTRACTOR ISSUES AND WEAK IMPLEMENTATION VS GROUP STANDARDS.

INOX GREEN ENERGY IPO ALLOTMENT DUE TODAY; INVESTORS CAN CHECK SUBSCRIPTION STATUS AHEAD OF PLANNED NSE/BSE LISTING. REPORT ALSO FLAGS THE SHARE LISTING DATE AND TIME.

TATVA: BOARD APPROVED AUDITED STANDALONE AND CONSOLIDATED FY26 RESULTS, RECOMMENDED FINAL DIVIDEND OF ₹2/SH (20%) SUBJECT TO SHAREHOLDER APPROVAL, AND APPOINTED COST AND INTERNAL AUDITORS FOR FY27

TATVA: BOARD APPROVED AUDITED STANDALONE & CONSOLIDATED FY26 RESULTS, RECOMMENDED FINAL DIVIDEND OF ₹2/SH. ALSO APPOINTED ZARNA THAKAR & ASSOCIATES AS COST AUDITOR AND RSM ASTUTE AS INTERNAL AUDITOR.

TATVA: BOARD APPROVED AUDITED STANDALONE & CONSOLIDATED Q4/FY26 RESULTS, RECORDED AUDITORS' REPORTS, AND RECOMMENDED FINAL DIVIDEND OF ₹2/SH (20%) SUBJECT TO SHAREHOLDER APPROVAL.

TANFACIND: TANFAC FY26 REVENUE ROSE TO ₹711 CR, HF CAPACITY DOUBLED TO 30K TPA, SOLAR-GRADE DHF 20K TPA COMMISSIONED, AND ~₹1,068 CR ORDERS LOCKED IN OVER 3.5 YRS.

AARTIDRUGS: AARTI DRUGS FILES FY26 INVESTOR PRESENTATION: Q4 REVENUE AT ₹720.3CR, FY26 REVENUE ₹2,567.7CR, EBITDA ₹311.6CR AND PAT ₹194.9CR, WITH FULL BALANCE SHEET AND SEGMENTAL BREAKDOWN.